IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) will present Phase 2 data on ortataxel at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois. Ortataxel is a third-generation orally bioavailable taxane, that has activity in tumor models resistant to paclitaxel and docetaxel. A study indicating activity in taxane-resistant non-small cell lung cancer had been previously reported. Results of the Phase 2 study in resistant breast cancer patients will be presented in a poster session on Monday, June 2, 2008. The abstract, entitled “Phase 2 Study of Ortataxel in Taxane-Resistant Breast Cancer” is available now on the ASCO website, www.asco.org.
